Abstract:The large and steadily growing demand for medicines combined with their inherent resource-intensive manufacturing necessitates a relentless push for their sustainable production. Pharmaceutical companies are constantly seeking to perform reliable life cycle assessments of their medicinal products and assess the true value of their sustainable development achievements; however, they find themselves impeded by the lack of a universal metric system that allows for objective quantification of the underlying core denominators. Guided by the unambivalent purpose of the United Nations Sustainable Development Goal 12, which aims at substantially reducing production waste by 2030, and driven by a vision to catalyze greener active pharmaceutical ingredient (API) manufacturing around the globe, the authors set out to overcome current obstacles by defining an improved model for the metric named innovation green aspiration level, iGAL 2.0. We propose yield and convergence as new key sustainability indicators and include a new formula for convergence with potential applicability in computer assisted synthesis planning (CASP) algorithms. The improved statistical model of iGAL 2.0 represents a valuable extension to the common API process waste metrics, process mass intensity (PMI) and complete E factor (cEF), by putting those measures into perspective: iGAL 2.0 enables determination of relative process greenness (RPG) to identify potentially underperforming and environmentally concerning processes early and thereby deliver environmental value. At the same time, iGAL 2.0 generates economic value since reduced waste correlates to lower API production costs. The metric is complemented by its scorecard companion to highlight the impact of innovation on reductions of API manufacturing waste, enabling scientists to readily communicate the value of their work to their peers, managers, and the general public. We believe that iGAL 2.0 can readily be adopted by pharmaceutical firms around the globe and thereby empower and inspire their scientists to make meaningful and significant contributions to global sustainability.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acssuschemeng.1c01940.Chapter 1, guidance for uniform analysis; Chapter 2, arrow schemes; Chapter 3, weighted convergence (CVwt); Chapter 4, API manufacturing process data; Chapter 5, updated iGAL equation; Chapter 6, methods for iGAL 2.0 scorecard; Chapter 7, statistical model for iGAL 2.0; and Chapter 8, utility of new CViGAL convergence formula in CASP tools (PDF)This article has not yet been cited by other publications.

Analysis of the change in molecular complexity of reaction products in process development activities at AstraZeneca over time.

An Automated Dual Modeling Approach to Accelerate Reaction Analysis and Optimization

Evaluating Molecular Complexity with Open-Source Machine Learning Approaches to Predict Process Mass Intensity

An analysis of published synthetic routes, route targets and reaction types (2000 – 2020)

Rapid Process Development of Chromatographic Process Using Direct Analysis in Real Time Mass Spectrometry As a Process Analytical Technology Tool

Continuous collective analysis of chemical reactions

Analysis of complex drugs by comprehensive two-dimensional gas chromatography and high-resolution mass spectrometry: detailed chemical description of the active pharmaceutical ingredient sodium bituminosulfonate and its process intermediates

Investigation of Quantitative X-ray Microscopy for Assessment of API and Excipient Microstructure Evolution in Solid Dosage Processing

High-Throughput Automated Data Analysis workflow for ADC Biotransformation Characterization

Characterization of Critical Reagents in Ligand-Binding Assays: Enabling Robust Bioanalytical Methods and Lifecycle Management

Accelerating reaction optimization through data-rich experimentation and machine-assisted process development

Improved iGAL 2.0 Metric Empowers Pharmaceutical Scientists to Make Meaningful Contributions to United Nations Sustainable Development Goal 12

Automated multifactorial design of experiment and Bayesian optimisation algorithm approaches to method development for the green analysis by supercritical fluid chromatography of a pharmaceutical ingredient

In depth characterization of physicochemical critical quality attributes of a clinical drug-dendrimer conjugate

Mapping Advantages and Challenges in Analytical Development for Fixed Dose Combination Products, a Review

Quantification of Amlodipine Maleate Content in Amorphous Solid Dispersions Produced by Fluidized Bed Granulation Using Process Analytical Technology Tools

Use of automation, dynamic image analysis, and process analytical technologies to enable data rich particle engineering efforts at the Drug Substance / Drug Product interface: A case study using Lovastatin

Development and in-line validation of a Process Analytical Technology to facilitate the scale up of coating processes

Advancing automation in Compound Management: a novel industrial process underpinning drug discovery

Rock-to-Pharma: Characterization of Shale Oil-Based Nonbiological Complex Drugs along the Production Process by High-Resolution Mass Spectrometry

Probing the Molecular-Level Interactions in an Active Pharmaceutical Ingredient (API) - Polymer Dispersion and the Resulting Impact on Drug Product Formulation